Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Basel, 19 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical
3 International ETFs for Investors Looking Beyond U.S. Stocks
09:00pm, Monday, 18'th May 2026
These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.
Roche Holding AG (RHHBY) Analyst/Investor Day Transcript
04:10pm, Monday, 18'th May 2026
Roche Holding AG (RHHBY) Analyst/Investor Day Transcript
Roche, Medicines Patent Pool sign deal to expand access to influenza drug
12:12pm, Monday, 18'th May 2026
Roche and the Medicines Patent Pool have signed a licensing agreement to expand access to the Swiss drugmaker's flu drug, Xofluza, in low- and middle-income countries, the organizations said on Mon
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
12:01pm, Monday, 18'th May 2026
RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
12:45pm, Friday, 15'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr
Olema: The Market Overreacted To Roche's SERD Failure
09:55am, Friday, 15'th May 2026
Olema Pharmaceuticals is rated a cautious buy, with upside potential tied to pivotal OPERA-01 Phase 3 trial results expected in fall 2026. Palazestrant differentiates itself as a CERAN with superior m
Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
06:15pm, Wednesday, 13'th May 2026
On Tuesday, Isomorphic Labs, the Alphabet-founded firm that uses AI to accelerate drug development, said that it had raised $2.1 billion from investors led by Thrive Capital. That's a boatload of cash
Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
09:35am, Tuesday, 12'th May 2026
The drugmaker's on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said.
Roche gets second European approval for Alzheimer's test
01:05am, Tuesday, 12'th May 2026
Swiss drugmaker Roche has received the CE mark - a European regulatory clearance allowing sale in the region - for its second Elecsys blood test for Alzheimer's disease, it said on Tuesday.
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
01:00am, Tuesday, 12'th May 2026
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and desig
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
02:04am, Thursday, 07'th May 2026
The deal seeks to bolster the artificial-intelligence offerings of Roche's diagnostics division, helping to accelerate clinical-therapy development.
Switzerland's Roche agrees to acquire US-based PathAI
01:51am, Thursday, 07'th May 2026
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
01:00am, Thursday, 07'th May 2026
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powere
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
01:00am, Thursday, 30'th Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from
